Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas have?
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas has 575 citations in the OpenAlex counts ScholarIQ stores.
When was Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas published?
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas has 2009 year in the ScholarIQ index.
What is the open-access status of Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas?
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas has bronze oa status in the ScholarIQ index.
What is the DOI of Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas?
The DOI for Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas is on the source record.
What is the PMID of Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas?
The PMID for Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas is on the source record.
What is the OpenAlex record for Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas?
The OpenAlex for Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas is on the source record.